Drug-resistant tuberculosis: what do we do now?

Détails

ID Serval
serval:BIB_8AE5D5A654C4
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Drug-resistant tuberculosis: what do we do now?
Périodique
Drugs
Auteur(s)
Telenti  A., Iseman  M.
ISSN
0012-6667 (Print)
Statut éditorial
Publié
Date de publication
02/2000
Volume
59
Numéro
2
Pages
171-9
Notes
Journal Article
Research Support, Non-U.S. Gov't
Review --- Old month value: Feb
Résumé
Drug-resistant tuberculosis (TB) represents a threat to TB control programmes. Erratic and inappropriate use of currently available medications, HIV-TB co-infection, and concern about transmission of drug-resistant strains in the general population all contribute to a worrying picture. What do we do now? In the last few years, there has been considerable progress in the understanding of mechanisms of action and resistance to antituberculosis agents, and in establishing the value of directly observed therapy in preventing treatment failure. However, a limited effort has been devoted to the development of new active compounds or of rapid diagnostic tests, and their relevance to global tuberculosis control has been questioned.
Mots-clé
Antitubercular Agents/*pharmacology Drug Design Humans Mycobacterium tuberculosis/*drug effects/genetics/pathogenicity Public Health Selection (Genetics) Tuberculosis, Multidrug-Resistant/*drug therapy Tuberculosis, Pulmonary/*drug therapy/pathology
Pubmed
Web of science
Création de la notice
25/01/2008 15:45
Dernière modification de la notice
03/03/2018 19:10
Données d'usage